Previous studies have found that using CCR2 inhibitors can significantly reverse the enrichment of macrophages in the tumor tissue, effectively reduce the tumor burden of CTCL, and thus, demonstrate good anti-tumor activity. This evidence concerns the gene CCR2 and neoplasm.